• Scientific Publications and Presentations

    Manuscripts 

    • Grafals M, Smith B, Murakami N3, Trabucco A, Hamill K, Marangos E, Gilligan H, Pomfret EA, Pomposelli JJ, Simpson MA, Azzi J2 Najafian N, Riella LV. Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. PLoS One. 2014 Aug 11;9(8):
    • Pomposelli JJ Broader liver sharing: the time has come. Liver Transpl. 2014 Oct;20(10):1155-6.
    • Emond JC1, Fisher RA, Everson G, Samstein B, Pomposelli JJ, Zhao B, Forney S, Olthoff KM, Baker TB, Gillespie BW, Merion RM. Changes in liver and spleen volumes after living liver donation: a report from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Liver Transpl. 2015 Feb;21(2):151-61.
    • Akoad ME, Pomfret EA. Laparoscopic live donor hepatectomy: random mutation or stepwise evolution? Am J Transplant. 2013 Sep;13(9):2243-4.
    • Schnelldorfer T, Jenkins RL, Birkett DH2, Georgakoudi I. From Shadow to Light: Visualization of Extrahepatic Bile Ducts Using Image-Enhanced Laparoscopy. Surg Innov. 2015 Apr;22(2):194-200.
    • Schnelldorfer T, Gagnon AI, Birkett RT, Reynolds G, Murphy KM, Jenkins RL. Staging laparoscopy in pancreatic cancer: a potential role for advanced laparoscopic techniques. J Am Coll Surg. 2014 Jun;218(6):1201-6.
    • DiMartini AF1, Dew MA, Butt Z, Simpson MA, Ladner DP, Smith AR, Hill-Callahan P, Gillespie BW. Patterns and Predictors of Sexual Function After Liver Donation: The Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Liver Transpl. 2015 Mar 16. doi: 10.1002/lt.24108. [Epub ahead of print]
    • Karagozian R, Grace ND, Qamar AA Hematologic indices improve with eradication of HCV in patients with cirrhosis and predict decompensation. Acta Gastroenterol Belg. 2014 Dec;77(4):425-32.
    • Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader D Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. Am J Cardiol. 2015 Jan 15;115(2):178-82.
    • Abougergi MS1, Karagozian R, Grace ND, Saltzman JR, Qamar AA ST Elevation Myocardial Infarction Mortality Among Patients With Liver Cirrhosis: A Nationwide Analysis Across a Decade. J Clin Gastroenterol. 2014 Oct 14.
    • Kumar S1, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci. 2014 Aug;59(8):1958-65.

    ATC 2014 Presentations

    • R. Khorzad, D. Woods,  R. Fischer, J. Guarrera, E. Pomfret,  M. Simpson,  S. Sherwani, A. Skaro, T. Baker, R. Ziomek, A. Daud, E. Reyes, E. Wymore, D. Ladner. A Failure Mode and Effects Analysis From Operating Room Setup to Incision in Living Liver Donors. (Abstract# 1488)
    • B. Smith, M. Grafals, N. Murakami, A. Trabucco, K. Hamill, E. Marangos, H. Gilligan, J. Pomposelli, E. Pomfret, J. Azzi, N. Najafi an, L. Riella. Immune Phenotyping and Efficacy of Low Dose ATG in Non-Sensitized Kidney Recipients Undergoing Early Steroid Withdrawal: A Randomized Pilot Study. (Abstract# C1796)
    • P. Mantry, P. Kwo, E. Coakley, H. Te, H. Vargas, R. Brown, Jr, F. Gordon, J. Levitsky, N. Terrault, J. Burton, Jr, W. Xie, C. Setze, P. Badri, R. Vilchez, X. Forns.  ABT-450/r/ABT-267+ABT-333+Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection. ( Abstract# 1325)
    • J. Emond, D. Grant, J. Pomposelli, A. Humar, N. Goodrich, R. Merion.  The Impact of Portal Flow Modulation (PFM) in the A2ALL Cohort Study.  (Abstract# 613)

    AASLD 2014 Presentations 

    • J.L. Mueller, L.Y. King, K.B. Johnson, K.E. Corey, R.T. Chung, B.C. Fuchs, K.K. Tanabe, F.D. Gordon, M. Simpson, M.P. Curry, L. Wei, T. Gao, L.D. Nephew, J. Lee. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study (ABSTRACT # 684)
    • P.S. Mantry , P.Y. Kwo, E. Coakley, W. Xie, C. Setze, P. Badri,R.A. Vilchez,  H.E. Vargas, R.S. Brown, F.D. Gordon, N. Terrault J. Levitsky,  J.R. Burton, X. Forns. High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-450/r/Ombitasvir+Dasabuvir Plus Ribavirin  (ABSTRACT # 198)
    • F.D. Gordon, A.A. Qamar, P.M. Hogan, L.V. Daponte, M. Simpson.  Insurance Approval Patterns for Second Generation DAAs (Abstract #1441)
    • N. Terrault, S.K Satapathy, G. Therapondos, F.D. Gordon, R. Shrestha, E.C. Verna, J. Campsen, J. Spivey, J. Rosenau, T.D. Schiano, K.R. Bhamidimarri, S. Linda, M. Vierling, G. Lake-Bakaar J.G. O'Leary, L.M. Kulik, D. Maluf S. Chavan, C.J. Dougherty.   Prevention of Hepatitis C Virus (HCV) Recurrence with Peri-Transplant Hepatitis C Immune Globulin Combined with Pre-Transplant (Pre-LT) Antiviral Therapy (AVT) (ABSTRACT #20)  
    • F.D. Gordon, D.S. Goldberg, N.P. R.M. Merion, Goodrich, A.S. Lok, E.C. Verna, N. Selzner, R. Stravitz , TITLE: Risk Factors for Recurrence of Primary Sclerosing Cholangitis in Live and Deceased Donor Liver Transplant (ABSTRACT #2)
    • F.D. Gordon, A.L. Kosinski, S.J. Coombs, P. Goucher, E.S. Aljahdli, E.A. Pomfret. Sofosbuvir + Simeprevir is Safe in Liver Transplant Recipients (ABSTRACT # 706) 
    • D. Ladner, D. Woods, E.A. Pomfret, M. Simpson, R.A. Fisher, J.V. Guarrera TITLE: “Patient positioning” in living liver donors – reinventing the wheel each time (ABSTRACT # 642)
  • Make An Appointment

    781.744.2500

    Jump to: